Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib

Matthew Allen, H. Follet, M. Khurana, M. Sato, David Burr

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Antiremodeling agents reduce bone loss in part through direct actions on osteoclasts. Their effects on osteoblasts and bone formation activity are less clear and may differ at sites undergoing modeling vs. remodeling. Skeletally mature intact beagles, 1-2 years old at the start of the study, were treated daily with clinically relevant doses of alendronate (0.10 or 0.20 mg/kg), risedronate (0.05 or 0.10 mg/kg), raloxifene (0.50 mg/kg), or vehicle (1 mL/kg). Dynamic bone formation parameters were histologically assessed on periosteal, endocortical/trabecular, and intracortical bone envelopes of the rib. Raloxifene significantly increased periosteal surface mineral apposition rate (MAR), a measure of osteoblast activity, compared to all other treatments (+108 to +175%, P < 0.02), while having no significant effect on MAR at either the endocortical/trabecular or intracortical envelope. Alendronate (both 0.10 and 0.20 doses) and risedronate (only the 0.10 dose) significantly (P ≤ 0.05) suppressed MAR on the endocortical/trabecular envelope, while none of the bisphosphonate doses significantly altered MAR at either the periosteal or intracortical envelopes compared to vehicle. Based on these results, we conclude that (1) at clinically relevant doses the two classes of antiremodeling agents, bisphosphonates and selective estrogen receptor modulators, exert differential effects on osteoblast activity in the canine rib and (2) this effect depends on whether modeling or remodeling is the predominant mechanism of bone formation.

Original languageEnglish
Pages (from-to)255-261
Number of pages7
JournalCalcified Tissue International
Volume79
Issue number4
DOIs
StatePublished - Oct 2006

Fingerprint

Ribs
Osteoblasts
Minerals
Canidae
Osteogenesis
Alendronate
Diphosphonates
Selective Estrogen Receptor Modulators
Osteoclasts
Bone and Bones
Risedronate Sodium
Raloxifene Hydrochloride

Keywords

  • Alendronate
  • Bisphosphonate
  • Periosteal
  • Raloxifene
  • Risedronate

ASJC Scopus subject areas

  • Endocrinology

Cite this

Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib. / Allen, Matthew; Follet, H.; Khurana, M.; Sato, M.; Burr, David.

In: Calcified Tissue International, Vol. 79, No. 4, 10.2006, p. 255-261.

Research output: Contribution to journalArticle

@article{cf6dd17fed8c4d0d976f4bb998fd591d,
title = "Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib",
abstract = "Antiremodeling agents reduce bone loss in part through direct actions on osteoclasts. Their effects on osteoblasts and bone formation activity are less clear and may differ at sites undergoing modeling vs. remodeling. Skeletally mature intact beagles, 1-2 years old at the start of the study, were treated daily with clinically relevant doses of alendronate (0.10 or 0.20 mg/kg), risedronate (0.05 or 0.10 mg/kg), raloxifene (0.50 mg/kg), or vehicle (1 mL/kg). Dynamic bone formation parameters were histologically assessed on periosteal, endocortical/trabecular, and intracortical bone envelopes of the rib. Raloxifene significantly increased periosteal surface mineral apposition rate (MAR), a measure of osteoblast activity, compared to all other treatments (+108 to +175{\%}, P < 0.02), while having no significant effect on MAR at either the endocortical/trabecular or intracortical envelope. Alendronate (both 0.10 and 0.20 doses) and risedronate (only the 0.10 dose) significantly (P ≤ 0.05) suppressed MAR on the endocortical/trabecular envelope, while none of the bisphosphonate doses significantly altered MAR at either the periosteal or intracortical envelopes compared to vehicle. Based on these results, we conclude that (1) at clinically relevant doses the two classes of antiremodeling agents, bisphosphonates and selective estrogen receptor modulators, exert differential effects on osteoblast activity in the canine rib and (2) this effect depends on whether modeling or remodeling is the predominant mechanism of bone formation.",
keywords = "Alendronate, Bisphosphonate, Periosteal, Raloxifene, Risedronate",
author = "Matthew Allen and H. Follet and M. Khurana and M. Sato and David Burr",
year = "2006",
month = "10",
doi = "10.1007/s00223-006-0031-5",
language = "English",
volume = "79",
pages = "255--261",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib

AU - Allen, Matthew

AU - Follet, H.

AU - Khurana, M.

AU - Sato, M.

AU - Burr, David

PY - 2006/10

Y1 - 2006/10

N2 - Antiremodeling agents reduce bone loss in part through direct actions on osteoclasts. Their effects on osteoblasts and bone formation activity are less clear and may differ at sites undergoing modeling vs. remodeling. Skeletally mature intact beagles, 1-2 years old at the start of the study, were treated daily with clinically relevant doses of alendronate (0.10 or 0.20 mg/kg), risedronate (0.05 or 0.10 mg/kg), raloxifene (0.50 mg/kg), or vehicle (1 mL/kg). Dynamic bone formation parameters were histologically assessed on periosteal, endocortical/trabecular, and intracortical bone envelopes of the rib. Raloxifene significantly increased periosteal surface mineral apposition rate (MAR), a measure of osteoblast activity, compared to all other treatments (+108 to +175%, P < 0.02), while having no significant effect on MAR at either the endocortical/trabecular or intracortical envelope. Alendronate (both 0.10 and 0.20 doses) and risedronate (only the 0.10 dose) significantly (P ≤ 0.05) suppressed MAR on the endocortical/trabecular envelope, while none of the bisphosphonate doses significantly altered MAR at either the periosteal or intracortical envelopes compared to vehicle. Based on these results, we conclude that (1) at clinically relevant doses the two classes of antiremodeling agents, bisphosphonates and selective estrogen receptor modulators, exert differential effects on osteoblast activity in the canine rib and (2) this effect depends on whether modeling or remodeling is the predominant mechanism of bone formation.

AB - Antiremodeling agents reduce bone loss in part through direct actions on osteoclasts. Their effects on osteoblasts and bone formation activity are less clear and may differ at sites undergoing modeling vs. remodeling. Skeletally mature intact beagles, 1-2 years old at the start of the study, were treated daily with clinically relevant doses of alendronate (0.10 or 0.20 mg/kg), risedronate (0.05 or 0.10 mg/kg), raloxifene (0.50 mg/kg), or vehicle (1 mL/kg). Dynamic bone formation parameters were histologically assessed on periosteal, endocortical/trabecular, and intracortical bone envelopes of the rib. Raloxifene significantly increased periosteal surface mineral apposition rate (MAR), a measure of osteoblast activity, compared to all other treatments (+108 to +175%, P < 0.02), while having no significant effect on MAR at either the endocortical/trabecular or intracortical envelope. Alendronate (both 0.10 and 0.20 doses) and risedronate (only the 0.10 dose) significantly (P ≤ 0.05) suppressed MAR on the endocortical/trabecular envelope, while none of the bisphosphonate doses significantly altered MAR at either the periosteal or intracortical envelopes compared to vehicle. Based on these results, we conclude that (1) at clinically relevant doses the two classes of antiremodeling agents, bisphosphonates and selective estrogen receptor modulators, exert differential effects on osteoblast activity in the canine rib and (2) this effect depends on whether modeling or remodeling is the predominant mechanism of bone formation.

KW - Alendronate

KW - Bisphosphonate

KW - Periosteal

KW - Raloxifene

KW - Risedronate

UR - http://www.scopus.com/inward/record.url?scp=33750549653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750549653&partnerID=8YFLogxK

U2 - 10.1007/s00223-006-0031-5

DO - 10.1007/s00223-006-0031-5

M3 - Article

C2 - 17033724

AN - SCOPUS:33750549653

VL - 79

SP - 255

EP - 261

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 4

ER -